Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall survival (OS), compared with paclitaxel alone in patients with previously ...
This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
Investigators conducted a meta-analysis of 4 randomized controlled trials including a total of more than 1000 men with prostate cancer.
HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...
Improvements seen in PFS, OS with Dato-DXd for previously untreated, locally recurrent inoperable or metastatic TNBC.
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival (OS) at 12 months. The update is the latest cut of ...
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, ...
PEACE-3 randomized 446 asymptomatic/mildly symptomatic mCRPC patients with bone metastases to enzalutamide ± radium-223, stratified by prior docetaxel, abiraterone, pain, and bone-targeting agents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results